Anti-Erythrocyte Allo-Immunization to Sickle Cell Disease Patients Followed in Transfusion Therapy Unit of the National Blood Transfusion Center of Abidjan Côte D’Ivoire
International Journal of Immunology
Volume 5, Issue 1, February 2017, Pages: 1-4
Received: Dec. 5, 2016; Accepted: Dec. 24, 2016; Published: Jan. 25, 2017
Views 3474      Downloads 165
Authors
Sekongo Y. M., Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire
Kouacou A. P. V., Immunology Service, University Hospital of Cocody, Abidjan, Côte d’Ivoire
Kouamenan G. S., Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire
Kassogue K., Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire
Siransy-Bogui L., Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire; Immunology Service, University Hospital of Cocody, Abidjan, Côte d’Ivoire
N’Guessan P., Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire
Danho N. C., Hematology Clinic, University Hospital of Yopougon, Abidjan, Côte d’Ivoire
Yeboah O. R., Immunology Service, University Hospital of Cocody, Abidjan, Côte d’Ivoire
Adou A. H., Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire
Dasse S. R., Immunology Service, University Hospital of Cocody, Abidjan, Côte d’Ivoire
Konate S., Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire
Article Tools
Follow on us
Abstract
The objective of this study is to evaluate the frequency of post-transfusion anti-erythrocyte allo-immunization to sickle cell patients in order to propose strategies of optimal blood safety in Côted'Ivoire. It is a prospective study (January to December 2013) of patients with major sickle cell disease enrolled in the transfusion therapy unit of the National Blood Transfusion Center (CNTS)in Abidjan. The reed blood cells have been phenotyped and compatibilized by indirect Coombs test in the ABO and Rh Kel systems. The search for irregular antibodies was performed before each transfusion episode. The incidence of post-transfusion anti-erythrocyte allo-immunization to the sickle cell disease patients were high (12/42 or 28.6%). We identified 14 allo-antibodies essentially anti-Rh specificity (12/14) with a high prevalence of anti-E allo-antibodies (6/14) and anti-C (4/14). None anti-Kel antibodies was found. This study raises the risk of allo-immunization in non-phenotyped and non-compatibilized transfusions, especially in sickle cell multitransfused. The erythrocyte phenotyping should be systematic to all major sickle cell patients.
Keywords
Sickle Cell Anemia, Anti-Erythrocyte Alloimmunization, Transfusion
To cite this article
Sekongo Y. M., Kouacou A. P. V., Kouamenan G. S., Kassogue K., Siransy-Bogui L., N’Guessan P., Danho N. C., Yeboah O. R., Adou A. H., Dasse S. R., Konate S., Anti-Erythrocyte Allo-Immunization to Sickle Cell Disease Patients Followed in Transfusion Therapy Unit of the National Blood Transfusion Center of Abidjan Côte D’Ivoire, International Journal of Immunology. Vol. 5, No. 1, 2017, pp. 1-4. doi: 10.11648/j.iji.20170501.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
F.Noizat-Pirenne. Séance éducationnelle. Transfusion et drépanocytose: axes d’optimisation de la sécurité transfusionnelle. Transfus Clin et Biol 2014; 2177–84.
[2]
Akré DP, Seka-Seka J. ,Dasse S.R., Kple-Faget P., Hien S., N’Guessan K., Sombo M.F. Recherche d’auto-anticorps anti-érythrocytaires dans un échantillon de patients drépanocytaires suivis au CHU de Cocody-Abidjan. Rev.I nt. Méd. 2008; 10(3): 7-12.
[3]
A.B. Diarra, A. Guindo B, B. Kouriba, A. Dorieb, D.T .Diabaté, S.I. Diawara, et al. Sécurité transfusionnelle et drépanocytose à Bamako, Mali: Séroprévalence de l’infections à VIH, VHB, VHC et allo-immunisation anti-Rh et Kell chez les drépanocytaires Transfusion Clinique et Biologique 2013; 20: 476–81.
[4]
Centre National de Transfusion Sanguine, Abidjan, Côte d’Ivoire. Rapport d’activités 2012.
[5]
Tayou C, et al. Le phenotype érythrocytaire dans le système ABO-Rh chez le donneur et le receveur de produits sanguins dans le milieu hospitalier camerounais: adapter l’offre à la demande. Rev Med Brux 2009;30: 145–216.
[6]
N. Meunier, M. Rodet, P. Bonin, P. Chadebech, B. Chami, K. Lee, et al. Étude d’une cohort de 206 patients drépanocytaires adultes transfusés: immunisation, risqué transfusionnel et resources en concentrés globulaires. Transfus ClinBiol 2008; 15: 377–82.
[7]
Siransy-Bogui L., Dembele B., Sekongo Y., Abisse S., Konaté S., and Sombo M. Phenotypic Profile of Rh and Kell Blood Group Systems among Blood Donors in Cote d’Ivoire, West Africa. Hindawi Publishing Corporation Journal of Blood Transfusion 2014, ID 309817: 4p.
[8]
Sekongo Y. M., Kassogue K., Kouamenan G. S., Konan S., Kouassi P, Lagou A.D., Kouacou-A.P., Konate S, Abisse A.. Mapping of Blood Group and Erythrocyt Phenotyp Rhesus and Kell to Sickle Cell Desease Patients in Transfusion Program in the Therapeutic Unit of the National Blood Transfusion Center (NBTC) of Abidjan Côte d’ivoire. International Journal of Immunology. 2015,4; 3: 47-51.
[9]
Maléwé K. Allo-immunisation anti-érythrocytaire post-transfusionnelle chez les drépanocytaires majeurs: etude primaire. Thèse, Med Abidjan, UFR des Sciences Médicales 2005: No 1249.
[10]
I. Ben Amor, N. Louati, H. Khemekhema, A. Dhieb, H.Rekik, M. Mdhaffar, et al. Immunisation anti-érythrocytaire dans les hémoglobinopathies: à propos de 84 cas Transfus Clin Biol 2012;19: 345–52.
[11]
Dembélé. A. Allo-immunisation anti-érythrocytaire post-transfusionnelle chez les drépanocytaires. Mémoire hématologie, Med Abidjan, UFR des Sciences Médicales 2013.
[12]
ALarif. L, Castro O, Ofusu Metal. (1986) HLA B35 is associated with red cell alloimmunization in sickle cell disease. Clin. Immunol. Immunopath.; 38(2): 178-83.
[13]
Olujohungbe A, Hambleton I, Stephens L, Serjeant B et Serjeant G (2001) Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom. Br J Haematol.; 113 (3): 661-5.
[14]
Pinto PC, Braga JA, Santos AM. Risk factors for allo-immunization in patients with sickle cell anemia. Rev Assoc Med Bras 2011; 57: 668–73.
[15]
C. Boulat. La transfusion du drépanocytaire Transfus Clin Biol 2013; 20: 68–71.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186